A marked and sustained reduction in LDL sterols by diet and cholestyramine in beta-sitosterolemia.
This study examines the therapeutic outcome of a low plant sterol diet and adjunctive drug therapy (cholestyramine) in the long term treatment of beta-sitosterolemia. A diet restricted in plant sterols, cholesterol and fat was implemented in a 48-year-old male beta-sitosterolemic patient. The plant sterols beta-sitosterol, campesterol and stigmasterol, and cholesterol content of the diet were quantitated by a gas chromatography method (GLC) during metabolic ward studies. Food table analysis of dietary sterols, while quantitatively similar to GLC, significantly underestimated the level of plant sterols and therefore overestimated dietary cholesterol intake. The duration of the study was 18 months. The effect of the diet over a period of 6 months on the sterol levels of plasma and individual lipoprotein fractions (VLDL, LDL, HDL) was evaluated. Apolipoproteins A-1 and B-100 levels were measured. The same parameters were assessed over the next 12 months with the adjunctive use of cholestyramine and dietary restrictions. The diet was effective in lowering total, VLDL, and LDL plant sterols by 37%, 59%, and 32% respectively. The low plant sterol diet did not change total plasma, VLDL or LDL cholesterol. With the addition of cholestyramine, total plasma and LDL cholesterol declined by 64 and 76%, respectively, while HDL-cholesterol remained unchanged. LDL plant sterols declined by 77%, while VLDL plant sterol showed no further change. The decline showed no discrimination among the individual plant sterols. One week after cholestyramine therapy, apolipoprotein B fell from 1.03 to 0.11 g/L, while apolipoprotein A rose from 1.29 to 1.79 g/L. These levels subsequently stabilized at 70% below (0.29 g/L) and 42% above (1.81 g/L) that of diet therapy alone. Xanthomas, angina pectoris, and intermittent claudication resolved during the diet and cholestyramine therapy period. Dietary restriction of plant sterols combined with cholestyramine therapy is an effective means of treating beta-sitosterolemia.
Parsons
H G
HG
Department of Pediatrics, Alberta Children's Hospital.
Jamal
R
R
Baylis
B
B
Dias
V C
VC
Roncari
D
D
D000328:Adult; D001055:Apolipoproteins B / Q000097:blood; D002791:Cholesterol, Dietary / Q000008:administration & dosage; D002792:Cholestyramine Resin / Q000627:therapeutic use*; D004032:Diet; D004041:Dietary Fats / Q000008:administration & dosage; D002149:Energy Intake; D004912:Erythrocytes / Q000378:metabolism; D006801:Humans; D008052:Lipid Metabolism, Inborn Errors / Q000178:diet therapy* / Q000188:drug therapy*; D008074:Lipoproteins / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood*; D008297:Male; D010840:Phytosterols / Q000008:administration & dosage*; D012855:Sitosterols / Q000097:blood*; D013261:Sterols / Q000097:blood
D001055:Apolipoproteins B; D002791:Cholesterol, Dietary; D004041:Dietary Fats; D008074:Lipoproteins; D008077:Lipoproteins, LDL; D010840:Phytosterols; D012855:Sitosterols; D013261:Sterols; D002792:Cholestyramine Resin; C025473:gamma-sitosterol